基于从肝论治的中药方剂联合抗甲状腺药物治疗甲状腺功能亢进症疗效分析

Efficacy of traditional Chinese medicine formulas based on liver regulation theory combined with anti-thyroid drugs for hyperthyroidism

  • 摘要: 目的系统评价中医药从肝论治方药联合抗甲状腺药物治疗甲状腺功能亢进症(甲亢)的临床疗效,为中医药应用于甲亢提供更加充分的循证医学证据。方法在中国知网、万方数据库、维普资讯数据库、中国生物医学文献数据库和Web of Science、PubMed、Cochrane library、Embase数据库中,检索自建库至2024年11月30日公开发表的中医药从肝论治甲亢的研究。筛选出符合纳排标准的研究后,对其进行研究质量评价,使用Revman 5.4软件对疗效进行系统再评价。结果总计纳入36篇公开发表的文章,共纳入2 616例患者,其中对照组1 309例、研究组1307例。比较2组甲状腺功能改善情况发现,研究组TSH升高程度高于对照组(I 2=93%,SMD为1.16,95%CI 0.81~1.51,P < 0.000 01),研究组降低FT3I 2=95%,SMD为-1.56,95%CI -1.98~-1.14,P < 0.000 01)和FT4I 2=96%,SMD为-1.78,95%CI -2.25~-1.30,P < 0.000 01)的程度优于对照组。另外,在改善症状方面研究组更显著(I 2=93%,SMD为-1.55,95%CI -1.95~-1.15,P < 0.000 01)。临床有效率对比发现,研究组有效率更高(I 2=0%,RR为1.23,95%CI 1.19~1.27,P < 0.000 01)。结论从肝论治方药联合抗甲状腺药物治疗甲亢可以更好地改善甲状腺功能,减轻临床症状,提高临床疗效,但尚缺乏大型的、高质量的临床研究。

     

    Abstract: ObjectiveTo systematically evaluate the clinical efficacy of traditional Chinese medicine (TCM) based on liver regulation theory combined with anti-thyroid drugs in the treatment of hyperthyroidism, aiming to provide more sufficient evidence of evidence-based medicine for the application of TCM in hyperthyroidism. MethodsStudies related to TCM treatment of hyperthyroidism based on liver regulation theory were retrieved from CNKI, Wanfang Database, Chongqing VIP Database, Chinese Biomedical Literature Database, Web of Science, PubMed, Cochrane Library and Embase until November 30, 2024. After screening the eligible studies, the quality of the studies was evaluated. Revman 5.4 software was used to systematically re-evaluate the efficacy. ResultsA total of 36 published studies were included, including 2 616 patients, 1 309 in the control group and 1 307 in the study group. Comparison of thyroid function improvement between two groups showed that TSH elevation in the study group was higher than that in the control group (I 2=93%,SMD=1.16,95% CI(0.81, 1.51), P < 0.000 01), and decreased FT3I 2=95%,SMD=-1.56,95%CI (-1.98, -1.14), P < 0.000 01) and FT4I 2=96%,SMD=-1.78,95%CI (-2.25,-1.30), P < 0.000 01) were better than those in the control group. In addition, the symptoms were more significantly mitigated in the study group (I 2=93%, SMD=-1.55, 95%CI (-1.95, 1.15), P < 0.000 01). The clinical response rate in the study group was higher than that in the control group (I 2=0%,RR=1.23, 95%CI (1.19, 1.27), P < 0.000 01). ConclusionTCM based on liver regulation theory combined with anti-thyroid drugs can better improve thyroid function, relieve clinical symptoms and improve clinical efficacy, which remains to be validated by large-scale, high-quality clinical research.

     

/

返回文章
返回